Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Oct 14:14:3297-3303.
doi: 10.2147/OPTH.S257541. eCollection 2020.

Dexamethasone/Netilmicin Eye Drops and Eye Gel for the Treatment of Ocular Inflammation After Micro-Incisional Vitreoretinal Surgery

Affiliations
Clinical Trial

Dexamethasone/Netilmicin Eye Drops and Eye Gel for the Treatment of Ocular Inflammation After Micro-Incisional Vitreoretinal Surgery

Antonio Rapisarda et al. Clin Ophthalmol. .

Abstract

Purpose: To evaluate the effect of dexamethasone/netilmicin (dexa/net) fixed combination in the treatment of ocular inflammation after sutureless micro-incisional vitreoretinal surgery (MIVS).

Patients and methods: This multicenter, open, randomized, active-controlled, parallel-group, clinical trial was run in 6 sites in Italy. Treatment started the day of surgery and continued 4 times daily for 14 days. Patients were 1:1 randomized to dexa/net (eyedrops solution and eye gel) or dexamethasone/tobramycin (dexa/tobra) eyedrops suspension and ointment. Viscous formulations (gel or ointment) were used alone during the early post-operative phase; afterwards, a combination of eye drops during daytime and viscous formulations at bedtime was adopted. The primary efficacy parameter evaluated was bulbar conjunctival hyperemia. Additional efficacy and safety parameters (palpebral conjunctival hyperemia, anterior chamber flare and cells, symptoms of ocular discomfort and ocular tolerance, adverse events and intraocular pressure) were also evaluated. Control visits were performed at day 1, day 4 and day 14 after surgery; the endpoint of the study was set at 14±2 days after surgery.

Results: A complete resolution of bulbar conjunctiva hyperaemia at the study end point was reached in 92.9% of patients treated with dexa/net and 75.0% of those treated with dexa/tobra (p=0.02, Fisher's exact test). No differences were observed between treatments for other efficacy parameters. Statistically significant differences in favour of dexa/net (p< 0.0001, ANOVA) were observed for most of subjective tolerance variables examined (blurred vision, foreign body sensation, stickiness, burning) starting day 1 after surgery when only the viscous formulations were used. No increase in intraocular pressure or adverse events was observed during the study.

Conclusion: The combination dexa/net is safe and effective in the treatment of post-operative inflammation following sutureless MIVS. In particular, the use of eye gel formulation is characterized by a great tolerability.

Keywords: fixed combination; tolerability; vitreoretinal surgery; xanthan gum.

PubMed Disclaimer

Conflict of interest statement

V Papa is an employee of SIFI SpA, manufacturer and supplier of Netildex. Current affiliation for S Rizzo is Università Cattolica Sacro Cuore Roma (Italy). C Iannacone reports personal fees from LB Research during the conduct of the study. A Rapisarda, P Arpa, PM Fantaguzzi, R Ratiglia and P Vaona are retirees. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Patients disposition.
Figure 2
Figure 2
Effects of treatment on hyperemia of the conjunctiva. Percentage of patients with a complete resolution of conjunctival hyperemia (score=0) at the end of the study (day 14 after surgery). A Fisher Exact Test was performed between the two groups of treatment.

References

    1. Kean Theng Oh JHD. Epiretinal Membrane; 2018. https://emedicine.medscape.com/article/1223882-overview#a4. accessed 25July 2019.
    1. Reddy RK, Lalezary M, Kim SJ, et al. Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) study: findings at 3 months. Clin Ophthalmol. 2013;7:1761–1769. - PMC - PubMed
    1. Sophie J, Bakri A, Capone A, et al. The American Society of Retina Specialists, https://www.asrs.org/patients/retinal-diseases/19/epiretinal-membranes. accessed 25July 2019.
    1. Nielsen RH. The use of dexamethasone in ophthalmologic steroid therapy: a preliminary report. Arch Ophthalmol. 1959;62(438–444):15. - PubMed
    1. Leibowitz HM, Kupferman A. Antiinflammatory medications. Int Ophthalmol Clin. 1980;20:117–134. - PubMed

LinkOut - more resources